Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Enrolled patients had a baseline or recent liver biopsy showing clinically significant MASLD (metabolic dysfunction-associated steatotic liver disease), defined as MASH with fibrosis stage 2 or 3 and a non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) 4 with a score of 1 or more in steatosis, lobular inflammation, and hepatocyte ballooning
doi:10.1016/j.fertnstert.2021.02.010
While side effects are rare, patients may experience mild swelling and redness, which typically subside within 2 to 3 days
Doctors can oversee gradual medication adjustments to prevent sudden metabolic disruptions
Input the Uniprot number P00766 for the protein or the sequence into the appropriate boxes
References WHO | Cardiovascular diseases (CVDs)
